Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 50-55-5 | Product Number: R0007
Reserpine
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
Product Documents:
| Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
|---|---|---|---|---|---|
| 1G |
$91.00
|
Contact Us | 4 | ≥100 |
|
| 5G |
$259.00
|
Contact Us | 1 | ≥40 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | R0007 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__3__3H__4__0N__2O__9 = 608.69 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive |
| Packaging and Container | 1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 50-55-5 |
| Reaxys Registry Number | 102015 |
| PubChem Substance ID | 87575589 |
| SDBS (AIST Spectral DB) | 10992 |
| Merck Index (14) | 8145 |
| MDL Number | MFCD00005091 |
Specifications
| Appearance | White to Light yellow to Light orange powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Specific rotation [a]20/D | -172 to -182 deg(C=1, DMF) |
Properties (reference)
| Specific Rotation | 177° (C=1,DMF) |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H302 : Harmful if swallowed. H360 : May damage fertility or the unborn child. H370 : Causes damage to organs. H372 : Causes damage to organs through prolonged or repeated exposure. H350 : May cause cancer. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P307 + P311 : IF exposed: Call a POISON CENTER or doctor/ physician. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. P405 : Store locked up. |
Related Laws:
| RTECS# | ZG0350000 |
Transport Information:
| HS Number | 2939.79.0000 |
Application
Efflux pump research
Reserpine has been reported to potentially inhibit efflux pumps in Staphylococcus aureus, Klebsiella pneumoniae etc. 1-3)
(The product is for research purpose only.)
(The product is for research purpose only.)
References
- 1) Inhibitory and Resistance-Modifying Potential of Plant-Based Alkaloids Against Methicillin-Resistant Staphylococcus aureus (MRSA)
- 2) Identification of natural compounds which inhibit biofilm formation in clinical isolates of Klebsiella pneumoniae.
- 3) Effectiveness of efflux pump inhibitors as biofilm disruptors and resistance breakers in gram-negative (ESKAPEE) bacteria
- Study of the relationship between the neurotransmitter store and adrenergic nerve block induced by reserpine and guanethidine
- The reserpine receptor (a review)
- How reserpine and chlorpromazine act: the impact of key discoveries on the history of psychopharmacology (a review)
- The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus
- A novel inhibitor of multidrug efflux pumps in Staphylococcus aureus
- Reserpine (a review on the description, properties, degradation, metabolism, and analysis of reserpine)
- Depletion and recovery of neuronal monoamine storage in rats of different ages treated with reserpine
- F. Ponzio, G. Achilli, G. Calderini, P. Ferretti, C. Perego, G. Toffano, S. Algeri, Neurobiol. Aging. 1984, 5, 101.
- Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia
- Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia
- Electroconvulsive shock: sustained decrease in norepinephrine uptake affinity in a reserpine model of depression
- Prejudices in pharmacology and pharmacotherapy: reserpine as a model for experimental research in depression
- Evaluation of the face validity of reserpine administration as an animal model of depression--Parkinson's disease association
- Antidepressant-like Effect of Tetrahydroisoquinoline Amines in the Animal Model of Depressive Disorder Induced by Repeated Administration of a Low Dose of Reserpine: Behavioral and Neurochemical Studies in the Rat
Application
Reserpine: A Central Nervous System Depressant and an Inhibitor of Multidrug Efflux Pumps in Bacteria
Reserpine is an alkaloid of rauwolfia sharing the yohimbine [Y0002] pentacyclic skeleton. Pharmacological studies have revealed that reserpine is a central nervous system depressant. Reserpine depletes stores of catecholamines (dopamine [A0305], noradrenaline [A0906] and adrenaline [A0173]) and 5-hydroxytryptamine [S0370] by inhibiting their accumulation in many organs, including the brain and adrenal medulla. The depression of the central nervous system results in a decreased heart rate and a lowering of arterial blood pressure.
In addition, some studies have reported that reserpine enhances the in vitro activity of fluoroquinolones, such as norfloxacin [N0817], ciprofloxacin [C2227, C2510] and sparfloxacin [S0840], against strains of Staphylococcus aureus expressing distinct efflux-related multidrug resistance pumps. (The product is for research purpose only.)
In addition, some studies have reported that reserpine enhances the in vitro activity of fluoroquinolones, such as norfloxacin [N0817], ciprofloxacin [C2227, C2510] and sparfloxacin [S0840], against strains of Staphylococcus aureus expressing distinct efflux-related multidrug resistance pumps. (The product is for research purpose only.)
References
Application
Reagen for myalgia model
References
Application
Reagent for pain model
Reference
Application
Reagent for schizophrenia model
References
PubMed Literature
Documents
Product Articles
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.